Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company's website is www.arcutis.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcutis Biotherapeutics, Inc. does
In the company’s own words
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company's website is www.arcutis.com.
Arcutis operates as a leading platform for dermatologic product development and commercialization, specializing in immuno-dermatology treatments. The company's core strategy centers on identifying molecules acting against validated biological targets in dermatology to develop best-in-class products addressing significant unmet needs in inflammatory skin conditions.
The company's primary commercial product is ZORYVE, a topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. ZORYVE is available in multiple formulations and concentrations across several approved indications. ZORYVE cream 0.3% is approved for treating plaque psoriasis in individuals aged 6 years and older in the United States and Canada, with a pending application for expansion to children as young as 2 years old. ZORYVE foam 0.3% is approved for seborrheic dermatitis in individuals aged 9 years and older and for plaque psoriasis of the scalp and body in individuals aged 12 and older. ZORYVE cream 0.15% treats mild to moderate atopic dermatitis in patients 6 years and older, while ZORYVE cream 0.05% addresses atopic dermatitis in children aged 2 to 5 years, with a pending application for infants as young as 3 months.
Beyond ZORYVE, Arcutis is advancing ARQ-234, a fusion protein checkpoint agonist acquired through the Ducentis BioTherapeutics acquisition in September 2022. ARQ-234 is being developed for atopic dermatitis as a complementary biologic treatment option and potentially for other inflammatory conditions.
The company holds exclusive worldwide rights to roflumilast as a topical product for dermatological indications through a licensing agreement with AstraZeneca. Arcutis maintains its own intellectual property portfolio with issued and pending patents providing exclusivity through 2037 for cream formulations and 2042 for foam formulations in the United States.
Arcutis has established international partnerships, including collaboration agreements with Hangzhou Zhongmei Huadong Pharmaceutical for Greater China and Southeast Asia and with Sato Pharmaceutical for Japan. The company estimates an actively prescription-treated patient market of approximately 17 million patients in the United States for topical therapies across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- WESTLAKE VILLAGE, CA
- Fiscal year end
- December
- CIK
- 1787306
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcutis Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcutis Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcutis Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcutis Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcutis Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”